If you’re not validating every edit with high-quality sequence analysis, you’re guessing — and guessing has no place in CRISPR, TALEN, or ZFN workflows.
Accurate gene editing QC is essential for verifying edits, detecting off-target events, and protecting downstream research or therapeutic development. Robust sequencing isn’t optional — it’s your safety net.
Scalable, High-Fidelity QC for Every Gene Editing Workflow
Ultra-efficient multiplexed prep for high-throughput construct screening, ideal for CRISPR guide validation, pooled editing campaigns, and engineered cell line development.
On-Target & Off-Target Gene Editing QC
Tagify® Adapter-Loaded Transposase for High-Confidence Tagmentation
Accurate characterization of on-target and off-target editing events is non-negotiable. Insertions, deletions, inversions, translocations — every outcome needs to be detected and verified. Yet standardized QC methods for gene editing are still early-stage, especially for off-target analysis. Most teams end up navigating inconsistent protocols, variable reagent quality, and limited scalability.
Reliable, QC-Verified Reagents for Tagmentation-Based Gene Editing Assays
Tagify reagents remove the uncertainty. Each lot is fully QC-checked and delivered as ready-to-use or custom-loaded hyperactive Tn5 or TnX, seqWell’s next-generation transposase engineered for dependable performance.
With Tagify, you get:
Consistent tagmentation performance
Scalable workflows for high-throughput QC
Reagents optimized for sensitive off-target detection
Broad Compatibility with Leading Gene Editing QC Methods
Tagify reagents integrate seamlessly with widely used transposase-based assays including:
"We’ve been asking for this. What’s great about Tagify is that it allows you to look at a specific place in the gene, and adapter concentration is taken care of. This system is really important because it provides us this opportunity to assess the consequences of gene editing in a semi-unbiased way. It shortens our process, makes it much more controlled, and lessens the amount of reagents we need to use.”
– Athea Vichas, Ph.D., Senior Principal Scientist of Gene Editing Analytical Development, Bristol Myers Squibb
“ExpressPlex is literally faster than Sanger. This changes everything for us. Basically, taking a two-day process to one day dramatically shortens time to data.”
– Henry Chan, Ph.D., Synthetic Biology Lead, Octant Bio